RAN-QUINAPRIL TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE)

Prieinama:

RANBAXY PHARMACEUTICALS CANADA INC.

ATC kodas:

C09AA06

INN (Tarptautinis Pavadinimas):

QUINAPRIL

Dozė:

40MG

Vaisto forma:

TABLET

Sudėtis:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 40MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

30/1000

Recepto tipas:

Prescription

Gydymo sritis:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Produkto santrauka:

Active ingredient group (AIG) number: 0123206004; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2014-10-17

Prekės savybės

_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
RAN
™
-QUINAPRIL
QUINAPRIL TABLETS USP
(5 MG, 10 MG, 20 MG AND 40 MG OF QUINAPRIL AS QUINAPRIL HYDROCHLORIDE)
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, ON
L6T 1C1
Date of Revision:
June 22, 2017
CONTROL NO. 206533
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
15
DOSAGE AND ADMINISTRATION
................................................................................
18
OVERDOSAGE
...................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 20
STORAGE AND STABILITY
............................................................................................
23
DOSAGE FORMS, COMPOSITION ANDPACKAGING
................................................. 23
PART II: SCIENTIFIC INFORMATION
..................................................................................
24
PHARMACEUTICAL INFORMATION
......................